Community-acquired pneumonia
Conditions
Interventions
TFLX tosilate hydrate was orally administered at a dose of 6 mg/kg (4.1 mg/kg of TFLX) BID for 5 to 10 days. The maximum dosage of TFLX tosilate hydrate did not exceed 180 mg/dose and 360mg/day (122.4
Sponsors
Society for the Use of Quinolones in Children
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with mild to severe CAP based on the severity assessment criteria in the Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan 2007. Patients younger than 16 years.
Exclusion criteria
Exclusion criteria: Patients who are not expected to recover by oral antimicrobial agents or those with urinary-tract infection. Patients who cannot take oral medications or those who refuse to take any drug. Patients who have a history of allergy to quinolone antibacterial agents. Patients who received antimicrobial agents before treatment with TFLX fine granules and whose conditions are improving. Patients who are suspected of having viral pneumonia or other diseases which are not expected to be resolved by TFLX fine granules. Other patients whom the physician deems to be ineligible for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy at the end of the treatment Bacteriological efficacy at the end of the treatment Adverse drug reactions | — |
Countries
Japan
Contacts
Public ContactHiroshi Sakata
Asahikawa Kosei Hospital Department of Pediatrics
Outcome results
None listed